Hyaluronidase-zzxf/Pertuzumab/Trastuzumab

Phase 3Monoclonal antibody

Hyaluronidase-zzxf/Pertuzumab/Trastuzumab is one of 83 biologic programs targeting Carcinosarcoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CarcinosarcomaActive, not recruiting

Endometrial CarcinomaSuspended

Prostate CancerActive, not recruiting

CarcinosarcomaPhase 3

Active, not recruiting

Endometrial CarcinomaPhase 3

Suspended

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Hyaluronidase-zzxf/Pertuzumab/Trastuzumab

MMayo Clinic

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Triptorelin Pamoate

Ipsen

Preclinical

2 7

Ifex

BBaxter Healthcare Corporation

Preclinical

—8

Xylocaine

CCitius Pharmaceuticals, Inc.

Xylocaine

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Completed·MMayo Clinic·Phase 2·NCT05730712·7 enrolled

Treatment1 trial

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Endometrial Carcinoma1 trial

A Phase III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Suspended·NNational Cancer Institute (NCI)·Phase 3·NCT05256225·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Hyaluronidase-zzxf/Pertuzumab/Trastuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyaluronidase-zzxf/Pertuzumab/Trastuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyaluronidase-zzxf/Pertuzumab/Trastuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

Hyaluronidase-zzxf/Pertuzumab/Trastuzumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

Treatment1 trial

Endometrial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News